ABOUT US

Experts in life science and deep tech

Discover more
OUR MISSION

We empower researchers, physicians and patients with ultra-sensitive whole-genome cancer detection.

Our SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using cutting-edge scientific breakthroughs, growing genomic and clinical databases, and sophisticated signal processing and AI, C2i enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development.

p22
OUR STORY

C2i Genomics was formally founded in 2019 and is based on technology developed at Cornell and the New York Genome Center. We are backed by top tier VCs.

Our Company is headquartered in the US with a CLIA lab in Cambridge, MA, and an R&D center in Israel. We have brought together outstanding professionals with multidisciplinary expertise in oncology, signal processing, bioinformatics and machine learning.

LOCATIONS

Our Offices

  • p151
    01.

    New York

    Our C2i Genomics headquarters is located in the thriving life science industry of NYC, in the modern and collaborative workspace at NYU BioLabs.

  • p151
    02.

    Haifa

    Our advanced R&D Center is located in Israel’s high-tech city of Haifa among top technology and life science companies.

  • p151
    03.

    Cambridge

    Our state-of-the-art CLIA certified lab is located in Cambridge, MA, surrounded by innovation and other leading research facilities.

LEADERSHIP

Meet our team

Loading…
close

OUR PARTNERSHIPS

Selected Investors

p22
CAREERS

Join our team

Join us in empowering researchers, physicians and patients with ultra-sensitive cancer detection.

View positions